Phase 3 Colorectal Cancer Trial, Recruiting NCT06134388 Sponsor: Tanta University Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 3 Colorectal Cancer Trial, Recruiting

NCT06134388
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with stage 4 (metastatic) colorectal cancer, confirmed through a tissue sample test
  • People aged between 18 and 65 years old, male or female
  • Women who could become pregnant must be using an accepted form of contraception
  • People who are well enough to carry out light activity and care for themselves, with a low score on a standard health performance scale (confirm with trial site)
  • People who have no medical reasons preventing them from receiving chemotherapy, including no significant suppression of bone marrow function
  • People whose liver is working at an adequate level, based on specific blood test results being within an acceptable range
  • People whose kidneys are working at an adequate level, based on specific blood test results being within an acceptable range
  • People whose blood counts (including red blood cells, white blood cells, platelets, and related measures) are within an acceptable range

Who may not be able to join:

  • Women who are pregnant or currently breastfeeding
  • People who have another active cancer that started in a part of the body other than the colon or rectum
  • People who have a known allergy to sulfasalazine or substances related to it
  • People who have kidney stones, severe vomiting, or severe diarrhoea
  • People who are currently taking certain medications that bind strongly to proteins in the blood or are heavily processed by the liver, such as certain blood-thinning medications (confirm with trial site for specific drugs)
  • People who have a blockage in the intestines or urinary tract
  • People who have a known condition called glucose-6-phosphate dehydrogenase deficiency, or a condition called porphyria
  • People who are currently being treated with sulfasalazine or mesalamine for ulcerative colitis or rheumatoid arthritis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +201151896761

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
1 September 2023
Est. completion
1 September 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Evaluating the change in the serum level of Ferritin; Evaluating the change in the serum level of Superoxide dismutase (SOD); Evaluating the change in the serum level of Nuclear factor-kappa B (NF-kB); Evaluating the change in the serum level of Bcl-2 associated X protein (Bax); Investigating the possible efficacy of sulfasalazine through evaluation of its impact on overall response rate (ORR).; Investigating the possible efficacy of sulfasalazine through evaluation of its impact on disease control rate (DCR).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov